Literature DB >> 3136155

C1 binding by murine IgM. The effect of a Pro-to-Ser exchange at residue 436 of the mu-chain.

J F Wright1, M J Shulman, D E Isenman, R H Painter.   

Abstract

We have examined a defect in complement activation in a mutant trinitrophenyl-binding pentameric murine monoclonal IgM which has serine replacing the proline normally found at position 436 in the protein. The mutant protein showed equivalent hapten binding but a 100-fold decreased ability to initiate complement-dependent lysis of trinitrophenyl-coupled erythrocytes at physiological ionic strength (mu = 0.15). C4b deposition mediated by the mutant protein was impaired to a similar degree. C1 bound by the mutant protein showed C1s to C1-s conversion, suggesting normal activation. When measured at reduced ionic strength (mu = 0.06), the C1 and C1q binding affinity of the mutant protein was approximately one-half that of the wild type. However, the C1 binding affinity of the mutant protein showed a greater dependence upon ionic strength such that at physiological ionic strength we estimate a 50-fold lower C1 binding affinity for the mutant molecule. Kinetic studies suggested that this difference in affinity was largely attributable to differences in association rates. In addition, a fixed proportion of the mutant molecules showed no C1 binding. We conclude that the defect in complement activation occurs at the level of C1 binding. Our data support a role for the C mu 3 domain (residues 340-440) in C1 binding by IgM.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3136155

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  The human IgM pentamer is a mushroom-shaped molecule with a flexural bias.

Authors:  Daniel M Czajkowsky; Zhifeng Shao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

3.  Requirement for complement in antibody responses is not explained by the classic pathway activator IgM.

Authors:  Christian Rutemark; Elisabeth Alicot; Anna Bergman; Minghe Ma; Andrew Getahun; Stephan Ellmerich; Michael C Carroll; Birgitta Heyman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

4.  Interaction of human complement with Sbi, a staphylococcal immunoglobulin-binding protein: indications of a novel mechanism of complement evasion by Staphylococcus aureus.

Authors:  Julia D Burman; Elisa Leung; Karen L Atkins; Maghnus N O'Seaghdha; Lea Lango; Pau Bernadó; Stefan Bagby; Dmitri I Svergun; Timothy J Foster; David E Isenman; Jean M H van den Elsen
Journal:  J Biol Chem       Date:  2008-04-22       Impact factor: 5.157

Review 5.  Complement in malaria immunity and vaccines.

Authors:  Liriye Kurtovic; Michelle J Boyle; D Herbert Opi; Alexander T Kennedy; Wai-Hong Tham; Linda Reiling; Jo-Anne Chan; James G Beeson
Journal:  Immunol Rev       Date:  2019-09-26       Impact factor: 12.988

6.  Intermolecular disulfide bonding in IgM: effects of replacing cysteine residues in the mu heavy chain.

Authors:  A C Davis; K H Roux; J Pursey; M J Shulman
Journal:  EMBO J       Date:  1989-09       Impact factor: 11.598

7.  The B cell receptor itself can activate complement to provide the complement receptor 1/2 ligand required to enhance B cell immune responses in vivo.

Authors:  Joerg Rossbacher; Mark J Shlomchik
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

8.  Targeted IgMs agonize ocular targets with extended vitreal exposure.

Authors:  Yvonne Chen; Maciej Paluch; Julie A Zorn; Sharmila Rajan; Brandon Leonard; Alberto Estevez; John Brady; Henry Chiu; Wilson Phung; Amin Famili; Minhong Yan; Claudio Ciferri; Marissa L Matsumoto; Greg A Lazar; Susan Crowell; Phil Hass; Nicholas J Agard
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.